An Observational Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI > 25 kg/m^2, in Real World Clinical Setting
Condition: Diabetes Mellitus, Type 2 Intervention: Drug: Canagliflozin 300 mg Sponsor: Johnson & Johnson Private Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2018 Category: Research Source Type: clinical trials
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases Interventions: Drug: Canagliflozin; Drug: Empagliflozin; Drug: Dapagliflozin; Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Drug: Glucagon-like Peptide-1 (GLP-1) Agonist; Drug: Anti-hyperglycemic Agents (AHA); Drug: Thiazolidinediones (TZD); Drug: Sulfonylureas (SU); Drug: Insulin Sponsor: Janssen Research & Development, LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2018 Category: Research Source Type: clinical trials
